L2Be Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
L2Be Pharma
Largest movements
- Cash +€22,385
up €22,385 (+22.2%), from €100,973 to €123,358
mainly Net result for the year (+€14,987) and Other debts (+€14,425)
- Deferred charges and accrued income -€11,954
down €11,954 (-88.3%), from €13,544 to €1,590
- Receivables within one year -€4,810
down €4,810 (-14.4%), from €33,432 to €28,622
of which Trade receivables: -€11,833
- Other debts +€14,425
up €14,425 (+25.2%), from €57,188 to €71,614
- Tax, wage and social debts -€8,355
down €8,355 (-28.7%), from €29,075 to €20,720
of which Taxes: -€8,355
- Other operating charges +€14,685
up €14,685 (+1947.3%), from €754 to €15,439
- Gross operating margin +€4,231
up €4,231 (+13.0%), from €32,550 to €36,781
- Taxes -€2,484
down €2,484 (-33.6%), from €7,386 to €4,902
- Financial income +€839
new in 2025: €839
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €147,948 | €153,570 | +€5,621 | +3.8% |
| Current assets | 29/58 | €147,948 | €153,570 | +€5,621 | +3.8% |
| Amounts receivable within one year | 40/41 | €33,432 | €28,622 | -€4,810 | -14.4% |
| Trade receivables | 40 | €33,432 | €21,599 | -€11,833 | -35.4% |
| Other amounts receivable | 41 | - | €7,023 | +€7,023 | |
| Cash at bank and in hand | 54/58 | €100,973 | €123,358 | +€22,385 | +22.2% |
| Deferred charges and accrued income | 490/1 | €13,544 | €1,590 | -€11,954 | -88.3% |
| Total equity and liabilities | 10/49 | €147,948 | €153,570 | +€5,621 | +3.8% |
| Equity | 10/15 | €57,221 | €57,221 | = | 0.0% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Reserves | 13 | €52,221 | €52,221 | = | 0.0% |
| Distributable reserves | 133 | €52,221 | €52,221 | = | 0.0% |
| Amounts payable | 17/49 | €90,728 | €96,349 | +€5,621 | +6.2% |
| Amounts payable within one year | 42/48 | €90,728 | €96,349 | +€5,621 | +6.2% |
| Trade debts | 44 | €4,465 | €4,016 | -€449 | -10.1% |
| Suppliers | 440/4 | €4,465 | €4,016 | -€449 | -10.1% |
| Taxes, remuneration and social security | 45 | €29,075 | €20,720 | -€8,355 | -28.7% |
| Taxes | 450/3 | €25,775 | €17,420 | -€8,355 | -32.4% |
| Remuneration and social security | 454/9 | €3,300 | €3,300 | = | 0.0% |
| Other amounts payable | 47/48 | €57,188 | €71,614 | +€14,425 | +25.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €161 | - | -€161 | |
| Other operating charges | 640/8 | €754 | €15,439 | +€14,685 | +1947.3% |
| Gross operating margin | 9900 | €32,550 | €36,781 | +€4,231 | +13.0% |
| Operating profit (loss) | 9901 | €31,634 | €21,342 | -€10,293 | -32.5% |
| Financial income | 75/76B | - | €839 | +€839 | |
| Recurring financial income | 75 | - | €839 | +€839 | |
| Financial charges | 65/66B | €2,186 | €2,292 | +€106 | +4.8% |
| Recurring financial charges | 65 | €2,186 | €2,292 | +€106 | +4.8% |
| Profit (loss) for the period before taxes | 9903 | €29,448 | €19,889 | -€9,559 | -32.5% |
| Income taxes | 67/77 | €7,386 | €4,902 | -€2,484 | -33.6% |
| Profit (loss) for the period | 9904 | €22,063 | €14,987 | -€7,075 | -32.1% |
| Profit (loss) for the period to be appropriated | 9905 | €22,063 | €14,987 | -€7,075 | -32.1% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 6 October 2026 via checked.be.